The 2027 Medicare Part D national average monthly bid amount is $296.05, the base beneficiary premium is $41.33, and the Part D Premium Stabilization Demonstration ends December 31, 2026, returning standalone prescription drug plans to unsubsidized market pricing for CY2027 (CMS, July 2026). CMS ended the demo on the finding that sponsors now have "sufficient experience under the redesigned Part D benefit" to support their bid assumptions. That is an actuarial claim, not a policy statement.

Key Takeaways

  • $296.05 national average monthly bid, a 24% increase over 2026 and the fourth consecutive year the bid has climbed more than 20%.
  • $41.33 base beneficiary premium, up 6% from $38.99 and held there by the statutory cap through CY2029 regardless of what the bid does. The delta lands in the federal subsidy.
  • $9.8 billion was the demonstration's two-year cost, covering 99% of PDP enrollees, on a $10 premium reduction and a $50 year-over-year change cap in 2026.
  • About $8 a month is the average enrollee-facing MA-PD Part D premium against roughly $36 for a standalone PDP under the demo. Standalone plans have no rebate reservoir.
  • Roughly 25 million people sit in a standalone PDP, about half the Part D-eligible population, and the change cap that suppressed sorting comes off for CY2027.

The Three Numbers That Reset Standalone Pricing

The $296.05 bid is a 24% increase over 2026 and the fourth consecutive year above 20% growth (Avalere, July 2026). The $41.33 base beneficiary premium is a 6% increase over $38.99, held to that ceiling by the Inflation Reduction Act cap governing base-premium growth through CY2029 (InsuranceNewsNet, July 2026). The gap between the two is the direct federal subsidy: roughly $254.72 per member per month before reinsurance and risk-sharing, before any demo dollars.

The demonstration paid out on top of that structure. Launched for CY2025 to smooth the transition into the redesigned benefit, the voluntary program cut the base beneficiary premium by $15 in 2025 and $10 in 2026, capped year-over-year premium changes at $35 then $50, and layered a government risk corridor over standard Part D reinsurance. Two-year cost: $9.8 billion, with 99% of PDP enrollees in a participating plan (KFF, July 2026).

MetricCY2025 (demo year 1)CY2026 (demo year 2)CY2027 (post-demo)
Base beneficiary premium$36.78 (net of $15 cut)$38.99 (net of $10 cut)$41.33
National average monthly bid$179.45$239 (approx.)$296.05
YoY change cap on plan premiums$35$50None (traditional pricing)
Government risk corridor overlayYesYesNo
Average PDP premium (weighted)~$28~$36Plan-specific; final Sept 2026

The 2026 average standalone PDP premium was about $36 per month under the demo. Without it, the reference point every PDP underwrites around in 2027 is the unshielded $41.33 base plus its own bid variance to the national average. CMS's distributional read puts about 25% of enrollees at no change or a decrease, about 30% under a $10 monthly increase, and about 45% at an $11 to $20 increase.

What "Sufficient Experience" Means Inside a Pricing Cell

Under the redesign effective January 1, 2025, the coverage gap disappeared, the annual out-of-pocket cap fell to $2,000, and manufacturers began paying a discount in the initial and catastrophic phases in place of the old coverage-gap discount (Inflation Reduction Act, Public Law 117-169). Each of those rewrote a pricing cell calibrated against a decade of pre-redesign experience.

What changes for CY2027 is the source of the assumption, not the method. In CY2025 and CY2026 a Part D actuary projecting catastrophic-phase claims cost had to work forward from pre-2025 experience adjusted for regulatory change, with the direction and magnitude of every adjustment carrying pure model risk. In CY2027 the same actuary starts from CY2025 actual claims, then applies trend, drug-mix shift and regulatory adjustments for CY2026 and CY2027 on top. That is the ordinary credibility ladder; it simply could not run on real experience for two years.

Year-one catastrophic-phase utilization came in materially above base cases, which is exactly the signal that motivates a large adverse adjustment in a first-real-experience bid cycle, and one plausible mechanic behind the 24% jump on top of the 20-plus-percent increases preceding it.

The base-premium cap then decides who pays for it. The 6% move from $38.99 to $41.33 sits far below the 24% bid increase because the statute caps base-premium growth through CY2029 regardless of the bid. Without the cap, the base premium would track the bid and land closer to $48 or $49 for CY2027. The cap absorbs the difference into the federal subsidy, which is why the direct subsidy per enrollee climbs faster than the beneficiary premium every year the cap binds, a path the Congressional Budget Office projections already assume.

Competitive geometry compounds the visible effect. A Medicare Advantage prescription drug plan builds a total-package bid and pulls rebate dollars from the medical side to buy down the drug premium the enrollee sees, which is how large carriers advertise near-zero drug premiums on plans carrying a full Part D benefit. The average enrollee-facing MA-PD Part D premium sat around $8 per month in 2026 against roughly $36 for a standalone PDP under the demo (KFF, July 2026). A standalone PDP has no medical bid, no rebate reservoir and no cross-subsidy path.

The Change Cap Suppressed the Sorting, and It Comes Off

The $50 year-over-year cap did more than moderate a sticker price. It suppressed the sorting mechanism every voluntary insurance market runs on. When premiums cannot move by their true cost differential, plans that would have priced higher stay artificially cheap, plans that would have priced lower cannot advertise the advantage, and the healthy-life exits that ordinarily follow a real price spike do not happen at the pace the underlying cost trend would produce.

Both channels return for CY2027, and they return at the point the redesigned benefit's full actuarial cost is loaded into standalone pricing for the first time. The two effects are not independent: the same year-one experience driving the 24% bid increase is what makes the unsuppressed price signal large enough to move enrollees.

Enrollment sets the stakes. Roughly 25 million people are in a standalone PDP in 2026, up from 22.8 million in 2024, about half the Part D-eligible Medicare population (KFF, July 2026). If even a modest slice of the healthier standalone enrollees moves to MA-PD, the standalone pool concentrates on higher-morbidity lives, and CY2027 experience feeds CY2028 bids at a stronger adverse-selection tilt than CY2027 bids themselves carry.

The two readings of the shutdown point at the same behavior. CMS Administrator Mehmet Oz framed it as a cost decision, and the $9.8 billion tracks (Healthcare Dive, July 2026). The market-mechanics reading is that the demo removed the volatility that would have triggered its own adverse selection and removed ordinary price discovery with it. Avalere's expectation of "further upward pressure on PDP premiums for 2028" follows from the same credibility mechanic.

Plan-specific premiums land in September, with open enrollment October 15 through December 7 (Medicare.gov). CMS's distribution is a bid-side output computed before any of that sorting occurs, which is precisely the quantity a $50 cap had been holding still.

Further Reading

Sources